This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olson, K. A. Articles by Fett, J. W. Search for Related Content PubMed PubMed Citation Articles by Olson, K. A. Articles by Fett, J. W.

Prevention of Human Prostate Tumor Metastasis in Athymic Mice by Antisense Targeting of Human Angiogenin¹

Center for Biochemical and Biophysical Sciences and Medicine and Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 [K. A. O., J. W. F.]; Departments of Dermatology and Pathology, Boston University School of Medicine, Boston, Massachusetts 02118-2394 [H. R. B.]; and Dako Corporation, Carpinteria, California 93013 [M. E. K.]

Purpose: Angiogenin is a potent positive mediator of neovascularization, a process required for both primary tumor growth and metastasis. In the present study, the effect of a fully phosphorothioated antisense oligodeoxynucleotide, designated JF2S, targeting the AUG translation initiation codon region of human angiogenin, on human prostate tumor development and metastasis in athymic mice was examined.

Experimental Design: JF2S was evaluated for its capacity to affect in vitro synthesis of angiogenin and subsequent tumorigenicity of transiently transfected prostate tumor cells in mice. In vivo treatment experiments were then conducted in which JF2S was used to prevent formation of tumors in an ectopic model and metastasis in an orthotopic model.

Results: Transient transfection of tumor cells with JF2S inhibited both angiogenin gene expression in vitro and tumorigenicity of these transfected cells in athymic mice. In therapy experiments, local treatment with JF2S completely protected mice from developing prostate tumors after s.c. injection of PC-3 human prostate tumor cells (P < 0.0001, survivor analysis). Most importantly, systemic prophylactic administration of JF2S prevented, in 47% of mice, formation of regional iliac lymph node micrometastases arising from primary tumors growing in the more natural orthotopic prostate setting (P = 0.0003, Fisher’s exact test). Furthermore, total protection from regional metastasis occurred in those mice in which JF2S treatment successfully diminished human angiogenin expression in vivo. Tumor-associated angiogenesis was also impaired by JF2S treatment. When therapy was delayed until all of the mice harbored primary tumors in the prostate, the incidence of regional metastasis was still significantly decreased (P < 0.005, survivor analysis).

Conclusions: These findings demonstrate that human prostate cancer establishment and spread in athymic mice is extremely susceptible to targeted disruption of tumor-derived human angiogenin gene expression. Therefore, angiogenin is a valid target against which to devise preventative strategies for prostate cancer metastasis.

This article has been cited by other articles:

				B. D. Smith and R. T. Raines Genetic selection for peptide inhibitors of angiogenin Protein Eng. Des. Sel., May 1, 2008; 21(5): 289 - 294. [Abstract] [Full Text] [PDF]

				N. Yoshioka, L. Wang, K. Kishimoto, T. Tsuji, and G.-f. Hu A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation PNAS, September 26, 2006; 103(39): 14519 - 14524. [Abstract] [Full Text] [PDF]

				S. Hirukawa, K. A. Olson, T. Tsuji, and G.-f. Hu Neamine Inhibits Xenografic Human Tumor Growth and Angiogenesis in Athymic Mice Clin. Cancer Res., December 15, 2005; 11(24): 8745 - 8752. [Abstract] [Full Text] [PDF]

				T. M. Katona, B. L. Neubauer, P. W. Iversen, S. Zhang, L. A. Baldridge, and L. Cheng Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors Clin. Cancer Res., December 1, 2005; 11(23): 8358 - 8363. [Abstract] [Full Text] [PDF]

				T. Tsuji, Y. Sun, K. Kishimoto, K. A. Olson, S. Liu, S. Hirukawa, and G.-f. Hu Angiogenin Is Translocated to the Nucleus of HeLa Cells and Is Involved in Ribosomal RNA Transcription and Cell Proliferation Cancer Res., February 15, 2005; 65(4): 1352 - 1360. [Abstract] [Full Text] [PDF]

				K. Kumar, M. Brady, and R. Shapiro Selective abolition of pancreatic RNase binding to its inhibitor protein PNAS, January 6, 2004; 101(1): 53 - 58. [Abstract] [Full Text] [PDF]

				R. Y. T. Kao, J. L. Jenkins, K. A. Olson, M. E. Key, J. W. Fett, and R. Shapiro A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity PNAS, July 23, 2002; 99(15): 10066 - 10071. [Abstract] [Full Text] [PDF]